# Anterra Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anterra-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Boston, US
- Total disclosed funding: $1.7M
- Latest round: Seed (Jun 1, 2016)
- Investors on record: 1

## About

Founded in 2014, Anterra Therapeutics operates out of Boston, US, where it specializes in biotechnology solutions aimed at metabolic conditions. The company has undergone a significant pivot in its strategy to enhance its product offerings. In January 2016, Anterra secured USD 1.7 mn in Seed funding led by RA Capital, marking its sole funding deal to date. The company has not disclosed any subsidiary or parent company relationships.

Anterra Therapeutics focuses on providing innovative biotechnology solutions designed to address the specific needs of its clientele. The company's core offerings include a comprehensive suite of therapeutic applications aimed at treating metabolic diseases. These products are engineered to improve patient outcomes through advanced biological mechanisms. Anterra primarily targets healthcare institutions and pharmaceutical companies in North America and Europe, allowing end users to access therapies that enhance treatment efficacy and patient care.

Anterra Therapeutics generates revenue through a structured model combining grants and partnerships with healthcare organizations. Business transactions typically involve collaborative agreements with research institutions, allowing access to its therapeutic products. The company may also engage in partnerships with pharmaceutical firms to broaden its reach and enhance visibility among potential clients. The flagship therapies within its portfolio command premium pricing due to their advanced formulations, enabling healthcare providers to achieve improved patient treatment outcomes.

Anterra Therapeutics generates revenue through a structured model combining grants and partnerships with healthcare organizations. Business transactions typically involve collaborative agreements with research institutions, allowing access to its therapeutic products. The company may also engage in partnerships with pharmaceutical firms to broaden its reach and enhance visibility among potential clients. The flagship therapies within its portfolio command premium pricing due to their advanced formulations, enabling healthcare providers to achieve improved patient treatment outcomes.

## Funding rounds

- Seed, Jun 1, 2016, $1.7M — RA Capital Management

## Investors

- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Seed